Literature DB >> 28066643

New strategies in esophageal carcinoma: promises and problems.

Zhaohui Xiong1, Jingxi He2, Xiaoxin Luke Chen3.   

Abstract

Entities:  

Year:  2016        PMID： 28066643      PMCID： PMC5179385          DOI： 10.21037/jtd.2016.11.22

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  19 in total

Review 1.  Personalized and targeted therapy of esophageal squamous cell carcinoma: an update.

Authors:  Yongjing Liu; Zhaohui Xiong; Andrea Beasley; Thomas D'Amico; Xiaoxin Luke Chen
Journal:  Ann N Y Acad Sci       Date:  2016-07-11       Impact factor: 5.691

2.  Perspective: The precision-oncology illusion.

Authors:  Vinay Prasad
Journal:  Nature       Date:  2016-09-08       Impact factor: 49.962

3.  Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs.

Authors:  Chul Kim; Vinay Prasad
Journal:  Mayo Clin Proc       Date:  2016-05-10       Impact factor: 7.616

Review 4.  Personalized targeted therapy for esophageal squamous cell carcinoma.

Authors:  Xiaozheng Kang; Keneng Chen; Yicheng Li; Jianying Li; Thomas A D'Amico; Xiaoxin Chen
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

Review 5.  Emerging immunotherapy for the treatment of esophageal cancer.

Authors:  SeungJu Jackie Oh; Songhee Han; Wooin Lee; A Craig Lockhart
Journal:  Expert Opin Investig Drugs       Date:  2016-03-24       Impact factor: 6.206

6.  Repression of Esophageal Neoplasia and Inflammatory Signaling by Anti-miR-31 Delivery In Vivo.

Authors:  Cristian Taccioli; Michela Garofalo; Hongping Chen; Yubao Jiang; Guidantonio Malagoli Tagliazucchi; Gianpiero Di Leva; Hansjuerg Alder; Paolo Fadda; Justin Middleton; Karl J Smalley; Tommaso Selmi; Srivatsava Naidu; John L Farber; Carlo M Croce; Louise Y Fong
Journal:  J Natl Cancer Inst       Date:  2015-08-18       Impact factor: 13.506

Review 7.  Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example.

Authors:  Jeffrey R Sachs; Kapil Mayawala; Satvik Gadamsetty; Soonmo Peter Kang; Dinesh P de Alwis
Journal:  Clin Cancer Res       Date:  2015-11-23       Impact factor: 12.531

8.  Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

Authors:  Christophe Le Tourneau; Jean-Pierre Delord; Anthony Gonçalves; Céline Gavoille; Coraline Dubot; Nicolas Isambert; Mario Campone; Olivier Trédan; Marie-Ange Massiani; Cécile Mauborgne; Sebastien Armanet; Nicolas Servant; Ivan Bièche; Virginie Bernard; David Gentien; Pascal Jezequel; Valéry Attignon; Sandrine Boyault; Anne Vincent-Salomon; Vincent Servois; Marie-Paule Sablin; Maud Kamal; Xavier Paoletti
Journal:  Lancet Oncol       Date:  2015-09-03       Impact factor: 41.316

9.  Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer.

Authors:  Valeria Santoro; Ruochen Jia; Hannah Thompson; Anke Nijhuis; Rosemary Jeffery; Konstantinos Kiakos; Andrew R Silver; John A Hartley; Daniel Hochhauser
Journal:  J Natl Cancer Inst       Date:  2015-12-30       Impact factor: 13.506

10.  Targeted therapy in gastroesophageal cancers: past, present and future.

Authors:  Janghee Woo; Stacey A Cohen; Jonathan E Grim
Journal:  Gastroenterol Rep (Oxf)       Date:  2015-10-27
View more
  3 in total

1.  Xiaoxin Chen: funding remains the greatest challenge to research due to constant improvement of technologies.

Authors:  Brad Li
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

2.  Establishment and genomic characterizations of patient-derived esophageal squamous cell carcinoma xenograft models using biopsies for treatment optimization.

Authors:  Jianling Zou; Ying Liu; Jingyuan Wang; Zhentao Liu; Zhihao Lu; Zuhua Chen; Zhongwu Li; Bin Dong; Wenwen Huang; Yanyan Li; Jing Gao; Lin Shen
Journal:  J Transl Med       Date:  2018-01-25       Impact factor: 5.531

3.  Selective synergistic anticancer effects of cisplatin and oridonin against human p53-mutant esophageal squamous carcinoma cells.

Authors:  Huiyu Yang; Jie Wang; Suliman Khan; Yuanying Zhang; Kuicheng Zhu; Enhui Zhou; Meiyuan Gong; Bingrong Liu; Quancheng Kan; Qi Zhang
Journal:  Anticancer Drugs       Date:  2022-01-01       Impact factor: 2.248
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.